Shayan Mohammadmoradi: ZEUS Trial-Inflammation Reduction Without Fewer Cardiovascular Events
Shayan Mohammadmoradi, Vascular Biology and Platelet Function Scientist at University of Kentucky, CEO at Moradi Enterprise, shared American Heart Association‘s post on LinkedIn:
“ZEUS at ScientificSessions26: monthly ziltivekimab cut free IL-6 by 76 percent and hs-CRP by 64 percent in 6,376 patients with ASCVD plus CKD.
3-point MACE: 17.6 percent vs 17.7 percent (HR 0.99).
Serious infections: 20.4 percent vs 17.9 percent.
Hitting the target didn’t lower events.
The point is neutral trials teach as much as positive ones so the question now is which patients, which target, and when.
Of course, Inflammation is still a valid target. Zeus tells us where it isn’t enough on its own.
American Heart Association shared a post on LinkedIn:
“Shayan Mohammadmoradi, discusses late breaking science results from ZEUS at ScientificSessions26.”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?
-
Nov 8, 2026, 17:36Paschalis Evangelidis: The Multifactorial Nature of Cardiovascular Risk in People With Hemophilia
-
Nov 8, 2026, 17:32Evangelos Panagiotopoulos: Apixaban Reduces Stroke and Major Bleeding Risk in Secondary Stroke Prevention
-
Nov 8, 2026, 17:27Danny Gaskin: Applications Open for the BBTS Specialist Certificate in Clinical Transfusion Practice
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week
-
Nov 8, 2026, 14:55Andra T.: Antiphospholipid Syndrome and Its Thrombotic Risks
-
Nov 8, 2026, 14:05Kausik Ray: Plaque-Guided Care for Better Coronary Outcomes